Nasdaq
$10.32▼ 1.90%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $867.8MShares out 84.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 8.7Pre-market26.08.07 22:16SCHEDULE 13GOwnership#●●●#●●●
Corvus Pharmaceuticals, Inc.
State Street Corp이 Corvus Pharmaceuticals, Inc.의 지분을 보유한 사실을 알리는 Schedule 13G 공시를 제출했습니다. 이는 기관 투자자가 특정 기업의 지분 5% 이상을 확보했음을 공식적으로 보고하는 대량지분 공시입니다.…more
$10.32-1.90%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.6After-hours26.08.07 05:0410-QEarnings
Corvus Pharmaceuticals, Inc.
코버스 파마슈티컬스(Corvus Pharmaceuticals)가 2026년 2분기 실적 보고서(10-Q)를 제출했습니다. 2026년 8월 6일 기준 발행 주식 수는 84,120,944주이며, 회사는 해당 분기 동안의 재무 상태와 운영 결과를 공시했습니다.…more
$10.32-1.90%vs prev closeView filingShare - 8.6After-hours26.08.07 05:028-KKey event
Corvus Pharmaceuticals, Inc.
코르버스 파마슈티컬스는 2026년 2분기 1,796만 달러의 순손실을 기록했으며, 6월 30일 기준 2억 1,520만 달러의 현금 및 유동자산을 보유하여 2028년 2분기까지 운영 자금을 확보했다. 주력 후보물질인 소켈리티닙(soquelitinib)은 PTCL 임상 3상 및 아토피 피부염 임상 2상을 진행 중이며, 올해 하반기 화농성 한선염 및 천식 임상 시험을 추가로 개시할 계획이다.…more
$10.32-1.90%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.30After-hours26.10.01 05:05#●●●#●●●#●●●
Corvus Pharmaceuticals Initiates Phase 1b Trial for Soquelitinib in Hidradenitis Suppurativa…more
Corvus Pharmaceuticals has commenced a Phase 1b clinical trial for its oral drug candidate, soquelitinib, targeting patients with hidradenitis suppurativa. The study aims to evaluate the safety and efficacy of the treatment as part of the company's efforts to expand the drug's therapeutic indications.…more
$10.32-1.90%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.3Pre-market26.09.03 21:30
●●●●●●●● ●●●●● ●●●●●●
Corvus Pharmaceuticals will participate in the 2026 Cantor Global Healthcare Conference to conduct investor meetings and a fireside chat. The presentation will highlight the company's ongoing clinical progress for its lead candidate, soquelitinib.…more
$10.32-1.90%vs prev close - 8.27Pre-market26.08.27 20:32
●●●●●●●● ●●●●● ●●●●●●
Corvus Pharmaceuticals published Phase 1/1b results for its T-cell lymphoma drug, soquelitinib, in the journal Blood. The study showed objective responses in 9 out of 24 patients with a median overall survival of 28.1 months.…more
$10.32-1.90%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report